Researchers visualized ALK fusion proteins in real time. They showed that ALK inhibitors reshape flexible protein regions to ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have ...

What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...

The goal is to find cures for ALK- positive lung cancer by targeting residual disease that remains after initial treatment. ALK Positive was founded on the principle that funding innovative, ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

In 5-year follow-up data from the phase III CROWN trial of ALK-positive advanced non-small cell lung cancer (NSCLC), patients receiving lorlatinib (Lorbrena) had the longest progression-free survival ...

Alecensa achieved a 4-year OS rate of 98.4% in resected ALK-positive early-stage NSCLC, outperforming chemotherapy. The ALINA study showed a 65% reduction in disease recurrence or death risk with ...

AUSTIN, Texas , Oct. 24, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University led have uncovered how targeted lung cancer drugs alter the shape and behavior of a ...